Analysis of Two Randomized Clinical Trials Identify No Cases of Longitudinal ... MarketWatch (press release) In the US, the ION(TM) Paclitaxel-Eluting Stent System and the PROMUS Element Plus Everolimus-Eluting Stent System were approved by the Food and Drug Administration in 2011. Xience V is a trademark of the Abbott Laboratories group of companies. Landmark Analysis Of Year Two Data From PLATINUM Workhorse Trial Demonstrates ... |
